ondansetron + pyridostigmine

**Ondansetron + pyridostigmine** is an oral combination therapy under investigation primarily for use in **myasthenia gravis**. Ondansetron is a selective serotonin 5-hydroxytryptamine subtype-3 (5-HT3) receptor antagonist commonly prescribed for prevention of nausea and vomiting, while pyridostigmine is a reversible acetylcholinesterase inhibitor indicated for improving muscle strength in myasthenia gravis and as prophylactic therapy against organophosphate poisoning. The combination is developed to reduce gastrointestinal side effects (especially nausea) that often limit the tolerability of pyridostigmine, potentially allowing for higher or more effective doses in patients. Animal pharmacology has shown that simultaneous administration may potentiate pyridostigmine-induced acetylcholinesterase inhibition, leading to heightened cholinergic effects, while separating their administration mitigates this effect. Clinical trials are ongoing to determine the safety and effect of the combination, particularly in people with anti-AChR positive myasthenia gravis who experience pyridostigmine-related GI toxicity[1][2][3][5][6][7].

Other names

pyridostigmine bromide + ondansetron